{"gene":"POU2F2","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1987,"finding":"POU2F2 (OTF-2) was purified to homogeneity from B cells as a protein complex of three peptides (62, 61, and 58.5 kDa), each capable of binding the octamer sequence 5'-ATGCAAAT, and the purified factor activated transcription from a kappa light chain promoter in vitro, establishing it as a B cell-specific transcription factor for immunoglobulin genes.","method":"Affinity chromatography purification, SDS-PAGE renaturation/DNA binding assay, in vitro transcription assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — protein purified to homogeneity, in vitro transcription reconstitution, multiple orthogonal methods (purification, DNA binding, functional transcription assay)","pmids":["3119226"],"is_preprint":false},{"year":1990,"finding":"OTF-2 (POU2F2) contains two distinct transcriptional activation domains required jointly for high-level transcription: a C-terminal proline-rich domain and an upstream domain with intermingled proline, glutamine, and leucine residues; point mutations in either glutamine or leucine clusters abolished function, indicating structural constraints beyond amino acid composition alone.","method":"Site-directed mutagenesis of OTF-2 cDNA, transient transfection into non-lymphoid cells, reporter gene transcription assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis of defined domains with functional readout, multiple mutants tested, replicated by multiple residue substitutions","pmids":["2328729"],"is_preprint":false},{"year":1990,"finding":"Purified OTF-1 and OTF-2 (POU2F2) have indistinguishable DNA-binding affinities and protein-DNA contacts on immunoglobulin or histone H2b promoters, and each can intrinsically activate transcription from these promoters to equivalent levels in OTF-depleted extracts; however, full immunoglobulin gene transcription in B-cell extracts requires an additional B-cell-specific regulatory component that cooperates with OTF-2.","method":"High-resolution DNase I footprinting, electrophoretic mobility shift assay (EMSA), in vitro transcription with OTF-depleted extracts, purified protein reconstitution","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with purified factors in depleted extracts, multiple orthogonal biochemical methods","pmids":["2123291"],"is_preprint":false},{"year":1990,"finding":"OTF-2 (POU2F2) interacts with the octamer element of the MOPC 141 immunoglobulin heavy-chain promoter, with footprinting revealing contacts extending over the heptamer element; an additional novel B-cell factor (NTF) binding the N element (5'-GGAACCTCCCCC) cooperates with OTF-2 to drive high-level B-cell-specific transcription, suggesting protein-protein interactions between NTF and OTF-2.","method":"EMSA, DNase I footprinting, in vitro transcription assay with purified factors","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal DNA binding and in vitro transcription, single lab, protein-protein interaction inferred but not directly demonstrated","pmids":["2109187"],"is_preprint":false},{"year":1990,"finding":"In a variant B-lymphoma cell line (1.3E2) defective in LPS-mediated kappa gene activation, neither NF-κB nor OTF-2 nuclear localization increases upon LPS stimulation, indicating that OTF-2 nuclear translocation is part of the LPS-activated transcriptional pathway for kappa light chain expression in B cells.","method":"Electrophoretic mobility shift assay on nuclear extracts, genetic variant cell line analysis","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single method (EMSA) but corroborated by a genetic model; localization/activation defect linked to functional outcome","pmids":["1689272"],"is_preprint":false},{"year":1991,"finding":"Anti-IgM antibody treatment of LPS-stimulated splenic B cells reduces OTF-2 (POU2F2) binding activity in nuclear extracts and alters its nuclear localization as detected by immunofluorescence, coinciding with suppression of IgH enhancer-driven transcription, placing OTF-2 downstream of surface Ig crosslinking signals.","method":"EMSA on nuclear extracts, in situ immunofluorescence with anti-OTF-2 antibodies, CAT reporter assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple methods (EMSA, immunofluorescence, reporter assay) in single lab; localization change tied to functional transcriptional outcome","pmids":["1658749"],"is_preprint":false},{"year":1992,"finding":"OTF-2 (POU2F2), but not OTF-1, positively activates transcription of the MHC class II gene DRA in vitro and in vivo; this activation requires an intact octamer element in the DRA promoter, as demonstrated by protein fractions enriched for OTF-2, recombinant OTF-2 produced by in vitro transcription/translation, and transient transfection with an OTF-2 expression vector.","method":"In vitro transcription with OTF-enriched fractions, in vitro transcription/translation of recombinant OTF-2, transient transfection with OTF-2 expression vector, octamer element mutation analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (in vitro reconstitution, recombinant protein, in vivo transfection with mutant element), single lab but convergent results","pmids":["1560002"],"is_preprint":false},{"year":2014,"finding":"Mutations in POU2F2 (OCT2) found in follicular lymphoma affect its transcriptional and functional properties, as measured by luciferase reporter assays, biological analysis of stably transduced cell lines, and global expression profiling, indicating that loss-of-function mutations in POU2F2 contribute to lymphoma pathogenesis.","method":"Exome sequencing, luciferase reporter assay, stable cell line transduction, global expression profiling","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays for transcriptional activity, single lab","pmids":["24435047"],"is_preprint":false},{"year":2015,"finding":"In gastric cancer cells, POU2F2 expression is induced by NF-κB activation; in turn, POU2F2 directly binds the ROBO1 promoter and activates its transcription, thereby promoting gastric cancer cell metastasis; miR-218 suppresses this axis by simultaneously targeting POU2F2, ROBO1, and IKK-β.","method":"Luciferase reporter assay, EMSA, ChIP-PCR, gain/loss-of-function experiments in vitro and in vivo (experimental metastasis animal model)","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (luciferase, EMSA, ChIP, in vivo model), functional pathway placement by rescue experiments","pmids":["26019213"],"is_preprint":false},{"year":2020,"finding":"In developing mouse retina, Pou2f2 (induced by Pou2f1) binds to a POU motif in the promoter of the rod-inducing factor Nrl to repress its expression; conditional inactivation of Pou2f2 in retinal progenitor cells increases Nrl expression and reduces cone photoreceptor production, while forced sustained Pou2f2 expression expands the cone production window.","method":"Promoter binding assay, conditional knockout mouse model (Cre-mediated), retroviral misexpression, quantification of cone vs. rod fate","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with specific molecular (Nrl expression) and cellular (cone/rod ratio) readouts, plus gain-of-function rescue; multiple orthogonal approaches","pmids":["32878923"],"is_preprint":false},{"year":2019,"finding":"In the developing mouse spinal cord, Pou2f2 expression in V2 interneurons is restricted by Onecut transcription factors; gain- or loss-of-function of Pou2f2 alters the position (distribution/migration) of V2 interneuron populations, placing Pou2f2 downstream of Onecut factors in a genetic pathway controlling interneuron diversification.","method":"Gain-of-function and loss-of-function experiments in mouse spinal cord, immunofluorescence for interneuron markers","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (Onecut → Pou2f2) with defined cellular phenotype, single lab","pmids":["31231191"],"is_preprint":false},{"year":2019,"finding":"In the developing mouse spinal cord, Pou2f2 is expressed in dorsal interneurons under regulation by Onecut factors; overexpression or inactivation of Pou2f2 leads to alterations in dI2, dI3, and Phox2a-positive dI5 differentiation and defects in dI2–dI6 interneuron distribution.","method":"Gain-of-function and loss-of-function experiments, immunofluorescence for dorsal interneuron markers","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss/gain of function with defined population-level phenotypic readouts, single lab","pmids":["31787878"],"is_preprint":false},{"year":2021,"finding":"POU2F2 promotes glioblastoma cell proliferation and aerobic glycolysis by directly binding to and activating transcription of the PDPK1 promoter; reconstitution of PDPK1 in POU2F2-knockdown cells rescues AKT/mTOR pathway activity, glycolysis, and proliferation, placing POU2F2 upstream of PDPK1 in a PI3K/AKT/mTOR signaling cascade.","method":"ChIP assay, luciferase reporter assay, shRNA knockdown, PDPK1 reconstitution/rescue experiments, PDPK1/AKT interaction inhibitor, in vivo xenograft model","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct promoter binding (ChIP + luciferase), epistatic rescue with reconstitution, in vivo validation; multiple orthogonal methods","pmids":["33931589"],"is_preprint":false},{"year":2021,"finding":"POU2F2 promotes lung cancer cell proliferation and motility by directly binding to and activating transcription of the AGO1 promoter, as demonstrated by ChIP and luciferase assays, with AGO1 knockdown abolishing the POU2F2-driven effects in vitro and in vivo.","method":"ChIP assay, luciferase reporter assay, shRNA knockdown, CCK-8/colony formation/Transwell assays, xenograft tumor model","journal":"BMC pulmonary medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding by ChIP and luciferase, epistatic rescue, single lab","pmids":["33832481"],"is_preprint":false},{"year":2023,"finding":"POU2F2 is a critical transcription factor driving escape from oncogene-induced senescence (OIS); its binding activity to cis-regulatory elements increases as cells escape OIS, and it exploits a pre-coded enhancer landscape to activate transcriptional programs enabling senescence escape and acquisition of transformed cell features.","method":"Dynamic multidimensional profiling (chromatin accessibility, transcriptomics), ChIP/CUT&RUN for POU2F2 binding, functional OIS escape assays","journal":"Cell genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide binding and functional escape assays, single lab, multiple omics methods","pmids":["37082139"],"is_preprint":false},{"year":2022,"finding":"CBX7 downregulates POU2F2 expression in bladder cancer cells; POU2F2 in turn activates PD-L1 expression, establishing a CBX7/POU2F2/PD-L1 regulatory axis; depletion of CBX7 results in resistance to PD-1 blockade.","method":"RNA-seq, knockdown experiments, Western blot, functional PD-1 blockade resistance assay","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, limited mechanistic detail in abstract; indirect pathway evidence, no direct binding assay reported for POU2F2-PD-L1","pmids":["35526483"],"is_preprint":false},{"year":2023,"finding":"POU2F2 and CEBPB cooperatively and additively enhance EDN1 (endothelin 1) transcription in vascular smooth muscle cells by binding to an enhancer region of the Edn1 promoter (-1309 to -1279 bp); overexpression of either factor increases EDN1 expression, and POU2F2 knockdown reduces it.","method":"Promoter activity analysis (luciferase), overexpression/knockdown experiments, EDN1 secretion ELISA","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — promoter mapping with luciferase, overexpression and knockdown with functional EDN1 readout, single lab, multiple methods","pmids":["36942826"],"is_preprint":false},{"year":2024,"finding":"POU2F2 transcriptionally upregulates PTPRG-AS1 lncRNA in triple-negative breast cancer by binding to its promoter; PTPRG-AS1 then acts as a competing endogenous RNA to sponge miR-376c-3p, thereby upregulating SLC7A11 and inhibiting ferroptosis.","method":"ChIP assay, dual-luciferase reporter assay, MTT/colony formation assay, Fe2+/ROS measurement, in vivo tumor growth assay","journal":"Epigenomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and luciferase, functional ferroptosis readout, single lab","pmids":["38318853"],"is_preprint":false},{"year":2024,"finding":"POU2F2 promotes PIK3CD transcription by directly binding to its promoter in B lymphocytes, thereby activating the Akt/mTOR signaling pathway and enhancing B cell proliferation; knockdown of POU2F2 suppresses B cell proliferation and IgG deposition in vivo.","method":"ChIP assay, luciferase reporter assay, shRNA knockdown, MTT/flow cytometry, IgG deposition assessment, Western blot","journal":"Nephrology (Carlton, Vic.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding (ChIP + luciferase), in vivo and in vitro functional readouts, single lab","pmids":["39401868"],"is_preprint":false},{"year":2024,"finding":"POU2F2 acts as a transcriptional repressor of SLC3A2 in chondrocytes; lncRNA HOXA11-AS interacts with POU2F2 (identified by RNA pulldown, mass spectrometry, and ChIP) to block its repressor activity, thereby increasing SLC3A2 expression and inhibiting ferroptosis in osteoarthritis.","method":"RNA pulldown, mass spectrometry, ChIP, RNA sequencing, in vitro and in vivo OA models","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (pulldown, MS, ChIP) identifying POU2F2 as a transcriptional repressor; single lab","pmids":["39251054"],"is_preprint":false},{"year":2025,"finding":"POU2F2 positively regulates transcription of the MARCH1 E3 ubiquitin ligase gene by binding its promoter; MARCH1 in turn interacts with and promotes ubiquitination and degradation of the tumor suppressor MYCT1, thereby driving AML cell proliferation and inhibiting apoptosis and differentiation.","method":"Promoter binding assay (ChIP/luciferase inferred from context), gain/loss-of-function, co-immunoprecipitation, ubiquitination assay, in vivo AML mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter activation and protein interaction demonstrated, epistatic rescue with MYCT1 knockdown, in vivo validation; single lab","pmids":["40533483"],"is_preprint":false},{"year":2025,"finding":"POU2F2 directly binds the PREX1 promoter and activates its transcription in AML cells, promoting mTOR pathway activation and AML malignant progression; PREX1 knockdown reverses POU2F2 overexpression-driven effects, establishing POU2F2 upstream of PREX1/mTOR in AML.","method":"Dual-luciferase assay, ChIP assay, Western blot, colony formation/CCK-8/Transwell assays, xenograft tumor model","journal":"Journal of biochemical and molecular toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding (dual-luciferase + ChIP), epistatic rescue, in vivo xenograft; single lab","pmids":["40317800"],"is_preprint":false},{"year":2025,"finding":"In the THBS1-mediated diabetic osteoporosis pathway, PPARγ (activated downstream of CD36) transcriptionally upregulates POU2F2, which then enhances osteoclastogenesis via c-FOS induction; genetic ablation of THBS1 or virtual screening inhibitor nasunin suppressed this CD36-PPARγ-POU2F2-c-FOS axis and reduced bone loss in T2D mice.","method":"ChIP-qPCR for PPARγ binding to POU2F2 promoter, Western blot, flow cytometry, TRAP staining, micro-CT, in vivo T2D mouse model, virtual screening","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP evidence for upstream regulation of POU2F2 by PPARγ, in vivo genetic ablation with bone phenotype readout; single lab","pmids":["41407214"],"is_preprint":false},{"year":2025,"finding":"In multiple myeloma, POU2F2 binds eccANKRD28 (an active enhancer eccDNA) and forms a protein complex with RUNX1 and RUNX2 to activate the promoters of oncogenes including IRF4, JUNB, IKZF3, RUNX3, and BCL2, driving bortezomib/lenalidomide resistance; CRISPR/Cas9-mediated elevation of eccANKRD28 desensitizes cells to treatment.","method":"H3K27ac ChIP-seq, scRNA-seq, scATAC-seq, CUT&Tag, CRISPR/Cas9, in vitro and in vivo drug resistance assays","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-omics binding evidence and functional CRISPR validation; POU2F2-RUNX complex formation inferred from motif co-occupancy rather than direct Co-IP; single lab","pmids":["40167268"],"is_preprint":false},{"year":2026,"finding":"POU2F2 is a crucial transcription factor mediating MIF-driven activation of SPP1+ tumor-associated macrophages in colorectal cancer; BCL9L is identified as a direct downstream transcriptional target of POU2F2 in this context, and blocking MIF signaling abolishes SPP1+TAM activation in vitro and in vivo.","method":"scRNA-seq interaction analysis, TAM co-culture model, liver metastasis in vivo model, mechanistic studies identifying POU2F2 as transcriptional regulator of BCL9L","journal":"International journal of biological sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanistic details for POU2F2-BCL9L binding not fully described in abstract; single lab, limited methodological detail","pmids":["41800265"],"is_preprint":false},{"year":2026,"finding":"POU2F2 directly binds to and activates the SPOCD1 promoter in lung adenocarcinoma cells (demonstrated by dual-luciferase, ChIP, and DNA pulldown assays), thereby enhancing PI3K/AKT pathway signaling and promoting cell proliferation; exercise suppresses POU2F2 expression, disrupting this axis.","method":"Dual-luciferase assay, ChIP assay, DNA pulldown, shRNA knockdown, CCK-8/EdU/flow cytometry/TUNEL assays, xenograft model with Ki67 IHC","journal":"Clinical & translational oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding by three orthogonal methods (luciferase, ChIP, DNA pulldown), in vivo validation; single lab","pmids":["41795741"],"is_preprint":false},{"year":2025,"finding":"Genetic loss of Pou2f2 in mouse spinal cord results in impaired development of two early-born motor neuron columns and re-specification of anterolateral system projection neurons as a later-born subset, placing Pou2f2 in a conserved sequential transcription factor cascade (Onecut2 → Pou2f2 → Pou3f1) that controls chronological diversification of spinal neuron subtypes.","method":"Conditional/constitutive mouse knockout, immunofluorescence for motor neuron and projection neuron markers, genetic epistasis analysis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined neuronal phenotype and pathway placement; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2025.05.27.656404"],"is_preprint":true}],"current_model":"POU2F2 (OTF-2) is a B cell-enriched POU-homeodomain transcription factor that binds octamer sequences (5'-ATGCAAAT) through its POU domain to activate immunoglobulin gene transcription and MHC class II (DRA) gene expression, possessing two structurally distinct transactivation domains (a C-terminal proline-rich domain and an upstream PQL domain); beyond B cells, it directly binds and activates the promoters of numerous target genes (PDPK1, AGO1, ROBO1, MARCH1, PREX1, PIK3CD, SPOCD1, PTPRG-AS1, SLC3A2) to regulate glycolytic reprogramming, AKT/mTOR signaling, cancer cell proliferation and metastasis, and ferroptosis; it also acts as a temporal transcription factor in retinal and spinal neuronal progenitors, where it represses the rod-fate determinant Nrl and controls the chronological order of neuron subtype production downstream of Onecut factors."},"narrative":{"mechanistic_narrative":"POU2F2 (OTF-2) is a POU-homeodomain transcription factor first identified as a B-cell factor that binds the octamer sequence 5'-ATGCAAAT and activates immunoglobulin gene transcription [PMID:3119226]. It engages octamer-containing promoters through DNA contacts that are biochemically indistinguishable from the ubiquitous OTF-1, yet drives full B-cell-specific transcription only in cooperation with additional B-cell-restricted factors, indicating that promoter selectivity arises from combinatorial partnerships rather than intrinsic binding differences [PMID:2123291, PMID:2109187]. High-level activation requires two structurally distinct transactivation domains — a C-terminal proline-rich domain and an upstream domain in which clustered glutamine and leucine residues are individually essential [PMID:2328729]. Beyond immunoglobulin loci, POU2F2 octamer-dependently activates the MHC class II gene DRA [PMID:1560002], and its nuclear binding activity is modulated downstream of LPS and surface-Ig signaling, linking it to B-cell activation pathways [PMID:1689272, PMID:1658749]. Loss-of-function mutations in POU2F2 contribute to follicular lymphoma pathogenesis [PMID:24435047]. In neuronal development, Pou2f2 acts as a temporal transcription factor downstream of Onecut factors: in retina it represses the rod-fate determinant Nrl to expand cone production [PMID:32878923], and in spinal cord it operates within a sequential Onecut2→Pou2f2→Pou3f1 cascade controlling the chronological diversification of interneuron and motor neuron subtypes [PMID:31231191, PMID:31787878, PMID:bio_10.1101_2025.05.27.656404]. In cancer, POU2F2 functions broadly as an oncogenic transcriptional activator that directly binds and induces target promoters — including PDPK1, AGO1, PREX1, SPOCD1, MARCH1, ROBO1 and PIK3CD — to drive PI3K/AKT/mTOR signaling, aerobic glycolysis, proliferation and metastasis [PMID:26019213, PMID:33931589, PMID:33832481, PMID:39401868, PMID:40533483, PMID:40317800, PMID:41795741], and it also acts as a transcriptional repressor of SLC3A2 modulating ferroptosis [PMID:39251054].","teleology":[{"year":1987,"claim":"Established the existence of a dedicated B-cell octamer-binding transcription factor for immunoglobulin genes, answering what protein activity drives kappa light chain transcription.","evidence":"Affinity purification to homogeneity, DNA-binding renaturation assay, and in vitro transcription from a kappa promoter","pmids":["3119226"],"confidence":"High","gaps":["Did not define the activation domains or sequence of the factor","Cooperating B-cell-specific components not yet identified"]},{"year":1990,"claim":"Mapped how POU2F2 activates transcription, showing two structurally constrained transactivation domains rather than a single composition-dependent activator.","evidence":"Site-directed mutagenesis of OTF-2 cDNA with reporter assays in non-lymphoid cells","pmids":["2328729"],"confidence":"High","gaps":["Coactivators contacted by each domain not identified","Structural basis of glutamine/leucine cluster requirement unresolved"]},{"year":1990,"claim":"Resolved the puzzle of why POU2F2 and ubiquitous OTF-1 bind octamers identically yet only POU2F2 confers B-cell-specific transcription, attributing specificity to cooperating B-cell factors.","evidence":"DNase footprinting, EMSA, and reconstituted in vitro transcription with purified factors in OTF-depleted extracts; identification of cooperating N-element factor (NTF)","pmids":["2123291","2109187"],"confidence":"High","gaps":["NTF/cooperating factor not molecularly identified","Direct protein-protein contact with POU2F2 inferred but not demonstrated"]},{"year":1992,"claim":"Extended POU2F2 target repertoire beyond immunoglobulin genes to MHC class II, showing octamer-dependent activation distinct from OTF-1.","evidence":"In vitro reconstitution, recombinant protein, transfection, and octamer-element mutation of the DRA promoter","pmids":["1560002"],"confidence":"High","gaps":["Genome-wide target scope unknown at this stage","Cell-type determinants of selectivity not addressed"]},{"year":1991,"claim":"Placed POU2F2 downstream of B-cell activation signals by linking its nuclear binding activity to LPS and surface-Ig crosslinking.","evidence":"EMSA and immunofluorescence on stimulated B cells, genetic variant cell line, reporter assays","pmids":["1689272","1658749"],"confidence":"Medium","gaps":["Mechanism of signal-induced nuclear translocation not defined","Single-method localization evidence per finding"]},{"year":2014,"claim":"Implicated POU2F2 in human disease by showing lymphoma-associated mutations alter its transcriptional function.","evidence":"Exome sequencing, luciferase reporters, stable transduction, and expression profiling in follicular lymphoma","pmids":["24435047"],"confidence":"Medium","gaps":["Causal driver status versus passenger mutation not fully resolved","Affected downstream gene programs only partly defined"]},{"year":2020,"claim":"Defined a developmental function as a temporal transcription factor, showing Pou2f2 represses Nrl to control cone-versus-rod photoreceptor fate timing.","evidence":"Promoter binding, conditional knockout, and retroviral misexpression in mouse retina with cone/rod quantification","pmids":["32878923"],"confidence":"High","gaps":["Direct vs indirect repression mechanism at Nrl not fully dissected","Cofactors mediating repression unknown"]},{"year":2019,"claim":"Positioned Pou2f2 within an Onecut-controlled genetic cascade governing spinal interneuron and motor neuron diversification.","evidence":"Gain/loss-of-function in mouse spinal cord with interneuron marker immunofluorescence; preprint extension to motor neuron columns and a Onecut2→Pou2f2→Pou3f1 cascade","pmids":["31231191","31787878","bio_10.1101_2025.05.27.656404"],"confidence":"Medium","gaps":["Direct transcriptional targets in neurons not identified","Spinal cord temporal cascade work partly preprint, not peer-reviewed"]},{"year":2025,"claim":"Established POU2F2 as a broad oncogenic transcriptional activator driving PI3K/AKT/mTOR signaling, glycolysis, proliferation and metastasis across diverse cancers via direct promoter activation of specific targets.","evidence":"ChIP, luciferase/dual-luciferase, DNA pulldown, knockdown with target reconstitution rescues, and xenograft/metastasis models across gastric, glioblastoma, lung, AML, breast, and other cancers","pmids":["26019213","33931589","33832481","39401868","40533483","40317800","41795741","38318853","40167268"],"confidence":"Medium","gaps":["Unifying determinants of which targets POU2F2 selects in a given tissue unclear","Repressor versus activator mode switching mechanism (e.g. SLC3A2) not mechanistically explained","Most findings are single-lab, single-cancer studies"]},{"year":null,"claim":"How POU2F2 switches between transcriptional activation and repression and selects context-specific targets across immune, neuronal, and cancer settings remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking cofactor binding to activator/repressor output","Genome-wide occupancy comparisons across cell types not integrated","Mechanism of upstream regulation (NF-κB, PPARγ, CBX7, miR-218) on POU2F2 levels incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,6,9,12,19]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,6,12]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,5]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,6,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,6,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9,10,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,18,21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,8,23]}],"complexes":[],"partners":["RUNX1","RUNX2","CEBPB","HOXA11-AS"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09086","full_name":"POU domain, class 2, transcription factor 2","aliases":["Lymphoid-restricted immunoglobulin octamer-binding protein NF-A2","Octamer-binding protein 2","Oct-2","Octamer-binding transcription factor 2","OTF-2"],"length_aa":479,"mass_kda":51.2,"function":"Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3') (PubMed:2904654, PubMed:7859290). Regulates IL6 expression in B cells with POU2AF1 (By similarity). Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression (PubMed:2901913, PubMed:2904654). Modulates transcription transactivation by NR3C1, AR and PGR (PubMed:10480874) Activates the U2 small nuclear RNA (snRNA) promoter","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P09086/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/POU2F2","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/POU2F2","total_profiled":1310},"omim":[{"mim_id":"612982","title":"MICRO RNA 210; MIR210","url":"https://www.omim.org/entry/612982"},{"mim_id":"607926","title":"HOST CELL FACTOR C2; HCFC2","url":"https://www.omim.org/entry/607926"},{"mim_id":"607394","title":"POU DOMAIN, CLASS 2, TRANSCRIPTION FACTOR 3; POU2F3","url":"https://www.omim.org/entry/607394"},{"mim_id":"600494","title":"POU DOMAIN, CLASS 3, TRANSCRIPTION FACTOR 2; POU3F2","url":"https://www.omim.org/entry/600494"},{"mim_id":"164176","title":"POU DOMAIN, CLASS 2, TRANSCRIPTION FACTOR 2; POU2F2","url":"https://www.omim.org/entry/164176"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Vesicles","reliability":"Enhanced"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":47.4}],"url":"https://www.proteinatlas.org/search/POU2F2"},"hgnc":{"alias_symbol":["OCT2"],"prev_symbol":["OTF2"]},"alphafold":{"accession":"P09086","domains":[{"cath_id":"1.10.260.40","chopping":"197-272","consensus_level":"high","plddt":93.6082,"start":197,"end":272},{"cath_id":"1.10.10.60","chopping":"305-354","consensus_level":"high","plddt":95.881,"start":305,"end":354}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09086","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09086-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09086-F1-predicted_aligned_error_v6.png","plddt_mean":58.84},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=POU2F2","jax_strain_url":"https://www.jax.org/strain/search?query=POU2F2"},"sequence":{"accession":"P09086","fasta_url":"https://rest.uniprot.org/uniprotkb/P09086.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09086/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09086"}},"corpus_meta":[{"pmid":"3119226","id":"PMC_3119226","title":"Identification and purification of a human lymphoid-specific octamer-binding protein (OTF-2) that activates transcription of an immunoglobulin promoter in vitro.","date":"1987","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/3119226","citation_count":349,"is_preprint":false},{"pmid":"24435047","id":"PMC_24435047","title":"Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24435047","citation_count":147,"is_preprint":false},{"pmid":"2328729","id":"PMC_2328729","title":"The cell type-specific octamer transcription factor OTF-2 has two domains required for the activation of transcription.","date":"1990","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2328729","citation_count":136,"is_preprint":false},{"pmid":"2904655","id":"PMC_2904655","title":"Drosophila homoeotic genes encode transcriptional activators similar to mammalian OTF-2.","date":"1988","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2904655","citation_count":109,"is_preprint":false},{"pmid":"2123291","id":"PMC_2123291","title":"Activation of octamer-containing promoters by either octamer-binding transcription factor 1 (OTF-1) or OTF-2 and requirement of an additional B-cell-specific component for optimal transcription of immunoglobulin promoters.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2123291","citation_count":102,"is_preprint":false},{"pmid":"1676977","id":"PMC_1676977","title":"Chromosomal location of the octamer transcription factors, Otf-1, Otf-2, and Otf-3, defines multiple Otf-3-related sequences dispersed in the mouse genome.","date":"1991","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1676977","citation_count":75,"is_preprint":false},{"pmid":"33931589","id":"PMC_33931589","title":"POU2F2 regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K/AKT/mTOR pathway.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33931589","citation_count":60,"is_preprint":false},{"pmid":"26019213","id":"PMC_26019213","title":"POU2F2-oriented network promotes human gastric cancer metastasis.","date":"2015","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/26019213","citation_count":57,"is_preprint":false},{"pmid":"32878923","id":"PMC_32878923","title":"Pou2f1 and Pou2f2 cooperate to control the timing of cone photoreceptor production in the developing mouse retina.","date":"2020","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32878923","citation_count":53,"is_preprint":false},{"pmid":"37082139","id":"PMC_37082139","title":"Escape from oncogene-induced senescence is controlled by POU2F2 and memorized by chromatin scars.","date":"2023","source":"Cell genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37082139","citation_count":38,"is_preprint":false},{"pmid":"31231191","id":"PMC_31231191","title":"Onecut Factors and Pou2f2 Regulate the Distribution of V2 Interneurons in the Mouse Developing Spinal Cord.","date":"2019","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31231191","citation_count":26,"is_preprint":false},{"pmid":"22671299","id":"PMC_22671299","title":"The chemoselective reactions of tyrosine-containing G-protein-coupled receptor peptides with [Cp*Rh(H2O)3](OTf)2, including 2D NMR structures and the biological consequences.","date":"2012","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/22671299","citation_count":25,"is_preprint":false},{"pmid":"2109187","id":"PMC_2109187","title":"Identification of a novel factor that interacts with an immunoglobulin heavy-chain promoter and stimulates transcription in conjunction with the lymphoid cell-specific factor OTF2.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2109187","citation_count":19,"is_preprint":false},{"pmid":"1689272","id":"PMC_1689272","title":"1.3E2, a variant of the B lymphoma 70Z/3, defective in activation of NF-kappa B and OTF-2.","date":"1990","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/1689272","citation_count":19,"is_preprint":false},{"pmid":"33965958","id":"PMC_33965958","title":"Long Non-Coding RNA ARAP1-AS1 Facilitates the Progression of Cervical Cancer by Regulating miR-149-3p and POU2F2.","date":"2021","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33965958","citation_count":18,"is_preprint":false},{"pmid":"1658749","id":"PMC_1658749","title":"Anti-IgM antibodies down modulate mu-enhancer activity and OTF2 levels in LPS-stimulated mouse splenic B-cells.","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1658749","citation_count":18,"is_preprint":false},{"pmid":"33832481","id":"PMC_33832481","title":"POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1.","date":"2021","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33832481","citation_count":17,"is_preprint":false},{"pmid":"38318853","id":"PMC_38318853","title":"POU2F2-mediated upregulation of lncRNA PTPRG-AS1 inhibits ferroptosis in breast cancer via miR-376c-3p/SLC7A11 axis.","date":"2024","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/38318853","citation_count":17,"is_preprint":false},{"pmid":"1560002","id":"PMC_1560002","title":"The B cell-specific nuclear factor OTF-2 positively regulates transcription of the human class II transplantation gene, DRA.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1560002","citation_count":15,"is_preprint":false},{"pmid":"31787878","id":"PMC_31787878","title":"Pou2f2 Regulates the Distribution of Dorsal Interneurons in the Mouse Developing Spinal Cord.","date":"2019","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31787878","citation_count":11,"is_preprint":false},{"pmid":"40167268","id":"PMC_40167268","title":"Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2-Mediated Transcriptional Network in Multiple Myeloma.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40167268","citation_count":8,"is_preprint":false},{"pmid":"36942826","id":"PMC_36942826","title":"CEBPB/POU2F2 modulates endothelin 1 expression in prehypertensive SHR vascular smooth muscle cells.","date":"2023","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36942826","citation_count":7,"is_preprint":false},{"pmid":"39251054","id":"PMC_39251054","title":"LncRNA HOXA11-AS intercepts the POU2F2-mediated downregulation of SLC3A2 in osteoarthritis to suppress ferroptosis.","date":"2024","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/39251054","citation_count":7,"is_preprint":false},{"pmid":"31782345","id":"PMC_31782345","title":"Overexpressing of POU2F2 accelerates fracture healing via regulating HMGA1/Wnt/β-catenin signaling pathway.","date":"2019","source":"Bioscience, biotechnology, and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31782345","citation_count":6,"is_preprint":false},{"pmid":"39994401","id":"PMC_39994401","title":"POU2F2+ B cells enhance antitumor immunity and predict better survival in non small cell lung cancer.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39994401","citation_count":5,"is_preprint":false},{"pmid":"35526483","id":"PMC_35526483","title":"CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35526483","citation_count":5,"is_preprint":false},{"pmid":"40533483","id":"PMC_40533483","title":"MARCH1, transcriptionally regulated by POU2F2, facilitates acute myeloid leukemia progression via inducing MYCT1 degradation.","date":"2025","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/40533483","citation_count":2,"is_preprint":false},{"pmid":"29889323","id":"PMC_29889323","title":"A Switch from Mechanistic Competition Mediated by a Combination of Temperature and Concentration Effects in the Oxidation Reaction of [FeII (N4Py/TPA)](OTf)2.","date":"2018","source":"Chemistry (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/29889323","citation_count":2,"is_preprint":false},{"pmid":"39401868","id":"PMC_39401868","title":"POU2F2 activates the Akt/mTOR signalling pathway and enhances B lymphocyte function during diabetic kidney disease by promoting PIK3CD transcription.","date":"2024","source":"Nephrology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/39401868","citation_count":1,"is_preprint":false},{"pmid":"40317800","id":"PMC_40317800","title":"Upregulation of PREX1 Expression by POU2F2 Promotes the Malignant Progression of Acute Myeloid Leukemia via the mTOR Pathway.","date":"2025","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/40317800","citation_count":1,"is_preprint":false},{"pmid":"41800265","id":"PMC_41800265","title":"CD44/POU2F2/BCL9L axis mediates MIF-driven SPP1+TAM activation in colorectal cancer metastasis.","date":"2026","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41800265","citation_count":0,"is_preprint":false},{"pmid":"41407214","id":"PMC_41407214","title":"Neutrophil-derived thrombospondin-1 (THBS1) drives type 2 diabetes-induced osteoporosis via CD36-PPARγ-POU2F2 signaling.","date":"2025","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/41407214","citation_count":0,"is_preprint":false},{"pmid":"41795741","id":"PMC_41795741","title":"Exercise inhibits proliferation and induces apoptosis of lung adenocarcinoma cells via the POU2F2-SPOCD1-PI3K/AKT signaling axis.","date":"2026","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/41795741","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.27.656404","title":"Evidence for chronological diversification of spinal neuron subtypes by a shared sequence of transcription factors","date":"2025-05-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.27.656404","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18791,"output_tokens":6876,"usd":0.079756,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15834,"output_tokens":3465,"usd":0.082897,"stage2_stop_reason":"end_turn"},"total_usd":0.162653,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"POU2F2 (OTF-2) was purified to homogeneity from B cells as a protein complex of three peptides (62, 61, and 58.5 kDa), each capable of binding the octamer sequence 5'-ATGCAAAT, and the purified factor activated transcription from a kappa light chain promoter in vitro, establishing it as a B cell-specific transcription factor for immunoglobulin genes.\",\n      \"method\": \"Affinity chromatography purification, SDS-PAGE renaturation/DNA binding assay, in vitro transcription assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — protein purified to homogeneity, in vitro transcription reconstitution, multiple orthogonal methods (purification, DNA binding, functional transcription assay)\",\n      \"pmids\": [\"3119226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"OTF-2 (POU2F2) contains two distinct transcriptional activation domains required jointly for high-level transcription: a C-terminal proline-rich domain and an upstream domain with intermingled proline, glutamine, and leucine residues; point mutations in either glutamine or leucine clusters abolished function, indicating structural constraints beyond amino acid composition alone.\",\n      \"method\": \"Site-directed mutagenesis of OTF-2 cDNA, transient transfection into non-lymphoid cells, reporter gene transcription assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis of defined domains with functional readout, multiple mutants tested, replicated by multiple residue substitutions\",\n      \"pmids\": [\"2328729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Purified OTF-1 and OTF-2 (POU2F2) have indistinguishable DNA-binding affinities and protein-DNA contacts on immunoglobulin or histone H2b promoters, and each can intrinsically activate transcription from these promoters to equivalent levels in OTF-depleted extracts; however, full immunoglobulin gene transcription in B-cell extracts requires an additional B-cell-specific regulatory component that cooperates with OTF-2.\",\n      \"method\": \"High-resolution DNase I footprinting, electrophoretic mobility shift assay (EMSA), in vitro transcription with OTF-depleted extracts, purified protein reconstitution\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with purified factors in depleted extracts, multiple orthogonal biochemical methods\",\n      \"pmids\": [\"2123291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"OTF-2 (POU2F2) interacts with the octamer element of the MOPC 141 immunoglobulin heavy-chain promoter, with footprinting revealing contacts extending over the heptamer element; an additional novel B-cell factor (NTF) binding the N element (5'-GGAACCTCCCCC) cooperates with OTF-2 to drive high-level B-cell-specific transcription, suggesting protein-protein interactions between NTF and OTF-2.\",\n      \"method\": \"EMSA, DNase I footprinting, in vitro transcription assay with purified factors\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal DNA binding and in vitro transcription, single lab, protein-protein interaction inferred but not directly demonstrated\",\n      \"pmids\": [\"2109187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"In a variant B-lymphoma cell line (1.3E2) defective in LPS-mediated kappa gene activation, neither NF-κB nor OTF-2 nuclear localization increases upon LPS stimulation, indicating that OTF-2 nuclear translocation is part of the LPS-activated transcriptional pathway for kappa light chain expression in B cells.\",\n      \"method\": \"Electrophoretic mobility shift assay on nuclear extracts, genetic variant cell line analysis\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single method (EMSA) but corroborated by a genetic model; localization/activation defect linked to functional outcome\",\n      \"pmids\": [\"1689272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Anti-IgM antibody treatment of LPS-stimulated splenic B cells reduces OTF-2 (POU2F2) binding activity in nuclear extracts and alters its nuclear localization as detected by immunofluorescence, coinciding with suppression of IgH enhancer-driven transcription, placing OTF-2 downstream of surface Ig crosslinking signals.\",\n      \"method\": \"EMSA on nuclear extracts, in situ immunofluorescence with anti-OTF-2 antibodies, CAT reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple methods (EMSA, immunofluorescence, reporter assay) in single lab; localization change tied to functional transcriptional outcome\",\n      \"pmids\": [\"1658749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"OTF-2 (POU2F2), but not OTF-1, positively activates transcription of the MHC class II gene DRA in vitro and in vivo; this activation requires an intact octamer element in the DRA promoter, as demonstrated by protein fractions enriched for OTF-2, recombinant OTF-2 produced by in vitro transcription/translation, and transient transfection with an OTF-2 expression vector.\",\n      \"method\": \"In vitro transcription with OTF-enriched fractions, in vitro transcription/translation of recombinant OTF-2, transient transfection with OTF-2 expression vector, octamer element mutation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (in vitro reconstitution, recombinant protein, in vivo transfection with mutant element), single lab but convergent results\",\n      \"pmids\": [\"1560002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Mutations in POU2F2 (OCT2) found in follicular lymphoma affect its transcriptional and functional properties, as measured by luciferase reporter assays, biological analysis of stably transduced cell lines, and global expression profiling, indicating that loss-of-function mutations in POU2F2 contribute to lymphoma pathogenesis.\",\n      \"method\": \"Exome sequencing, luciferase reporter assay, stable cell line transduction, global expression profiling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays for transcriptional activity, single lab\",\n      \"pmids\": [\"24435047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In gastric cancer cells, POU2F2 expression is induced by NF-κB activation; in turn, POU2F2 directly binds the ROBO1 promoter and activates its transcription, thereby promoting gastric cancer cell metastasis; miR-218 suppresses this axis by simultaneously targeting POU2F2, ROBO1, and IKK-β.\",\n      \"method\": \"Luciferase reporter assay, EMSA, ChIP-PCR, gain/loss-of-function experiments in vitro and in vivo (experimental metastasis animal model)\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (luciferase, EMSA, ChIP, in vivo model), functional pathway placement by rescue experiments\",\n      \"pmids\": [\"26019213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In developing mouse retina, Pou2f2 (induced by Pou2f1) binds to a POU motif in the promoter of the rod-inducing factor Nrl to repress its expression; conditional inactivation of Pou2f2 in retinal progenitor cells increases Nrl expression and reduces cone photoreceptor production, while forced sustained Pou2f2 expression expands the cone production window.\",\n      \"method\": \"Promoter binding assay, conditional knockout mouse model (Cre-mediated), retroviral misexpression, quantification of cone vs. rod fate\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with specific molecular (Nrl expression) and cellular (cone/rod ratio) readouts, plus gain-of-function rescue; multiple orthogonal approaches\",\n      \"pmids\": [\"32878923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In the developing mouse spinal cord, Pou2f2 expression in V2 interneurons is restricted by Onecut transcription factors; gain- or loss-of-function of Pou2f2 alters the position (distribution/migration) of V2 interneuron populations, placing Pou2f2 downstream of Onecut factors in a genetic pathway controlling interneuron diversification.\",\n      \"method\": \"Gain-of-function and loss-of-function experiments in mouse spinal cord, immunofluorescence for interneuron markers\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (Onecut → Pou2f2) with defined cellular phenotype, single lab\",\n      \"pmids\": [\"31231191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In the developing mouse spinal cord, Pou2f2 is expressed in dorsal interneurons under regulation by Onecut factors; overexpression or inactivation of Pou2f2 leads to alterations in dI2, dI3, and Phox2a-positive dI5 differentiation and defects in dI2–dI6 interneuron distribution.\",\n      \"method\": \"Gain-of-function and loss-of-function experiments, immunofluorescence for dorsal interneuron markers\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss/gain of function with defined population-level phenotypic readouts, single lab\",\n      \"pmids\": [\"31787878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"POU2F2 promotes glioblastoma cell proliferation and aerobic glycolysis by directly binding to and activating transcription of the PDPK1 promoter; reconstitution of PDPK1 in POU2F2-knockdown cells rescues AKT/mTOR pathway activity, glycolysis, and proliferation, placing POU2F2 upstream of PDPK1 in a PI3K/AKT/mTOR signaling cascade.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, shRNA knockdown, PDPK1 reconstitution/rescue experiments, PDPK1/AKT interaction inhibitor, in vivo xenograft model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct promoter binding (ChIP + luciferase), epistatic rescue with reconstitution, in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"33931589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"POU2F2 promotes lung cancer cell proliferation and motility by directly binding to and activating transcription of the AGO1 promoter, as demonstrated by ChIP and luciferase assays, with AGO1 knockdown abolishing the POU2F2-driven effects in vitro and in vivo.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, shRNA knockdown, CCK-8/colony formation/Transwell assays, xenograft tumor model\",\n      \"journal\": \"BMC pulmonary medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding by ChIP and luciferase, epistatic rescue, single lab\",\n      \"pmids\": [\"33832481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"POU2F2 is a critical transcription factor driving escape from oncogene-induced senescence (OIS); its binding activity to cis-regulatory elements increases as cells escape OIS, and it exploits a pre-coded enhancer landscape to activate transcriptional programs enabling senescence escape and acquisition of transformed cell features.\",\n      \"method\": \"Dynamic multidimensional profiling (chromatin accessibility, transcriptomics), ChIP/CUT&RUN for POU2F2 binding, functional OIS escape assays\",\n      \"journal\": \"Cell genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide binding and functional escape assays, single lab, multiple omics methods\",\n      \"pmids\": [\"37082139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CBX7 downregulates POU2F2 expression in bladder cancer cells; POU2F2 in turn activates PD-L1 expression, establishing a CBX7/POU2F2/PD-L1 regulatory axis; depletion of CBX7 results in resistance to PD-1 blockade.\",\n      \"method\": \"RNA-seq, knockdown experiments, Western blot, functional PD-1 blockade resistance assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, limited mechanistic detail in abstract; indirect pathway evidence, no direct binding assay reported for POU2F2-PD-L1\",\n      \"pmids\": [\"35526483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"POU2F2 and CEBPB cooperatively and additively enhance EDN1 (endothelin 1) transcription in vascular smooth muscle cells by binding to an enhancer region of the Edn1 promoter (-1309 to -1279 bp); overexpression of either factor increases EDN1 expression, and POU2F2 knockdown reduces it.\",\n      \"method\": \"Promoter activity analysis (luciferase), overexpression/knockdown experiments, EDN1 secretion ELISA\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — promoter mapping with luciferase, overexpression and knockdown with functional EDN1 readout, single lab, multiple methods\",\n      \"pmids\": [\"36942826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"POU2F2 transcriptionally upregulates PTPRG-AS1 lncRNA in triple-negative breast cancer by binding to its promoter; PTPRG-AS1 then acts as a competing endogenous RNA to sponge miR-376c-3p, thereby upregulating SLC7A11 and inhibiting ferroptosis.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, MTT/colony formation assay, Fe2+/ROS measurement, in vivo tumor growth assay\",\n      \"journal\": \"Epigenomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and luciferase, functional ferroptosis readout, single lab\",\n      \"pmids\": [\"38318853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"POU2F2 promotes PIK3CD transcription by directly binding to its promoter in B lymphocytes, thereby activating the Akt/mTOR signaling pathway and enhancing B cell proliferation; knockdown of POU2F2 suppresses B cell proliferation and IgG deposition in vivo.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, shRNA knockdown, MTT/flow cytometry, IgG deposition assessment, Western blot\",\n      \"journal\": \"Nephrology (Carlton, Vic.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding (ChIP + luciferase), in vivo and in vitro functional readouts, single lab\",\n      \"pmids\": [\"39401868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"POU2F2 acts as a transcriptional repressor of SLC3A2 in chondrocytes; lncRNA HOXA11-AS interacts with POU2F2 (identified by RNA pulldown, mass spectrometry, and ChIP) to block its repressor activity, thereby increasing SLC3A2 expression and inhibiting ferroptosis in osteoarthritis.\",\n      \"method\": \"RNA pulldown, mass spectrometry, ChIP, RNA sequencing, in vitro and in vivo OA models\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (pulldown, MS, ChIP) identifying POU2F2 as a transcriptional repressor; single lab\",\n      \"pmids\": [\"39251054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"POU2F2 positively regulates transcription of the MARCH1 E3 ubiquitin ligase gene by binding its promoter; MARCH1 in turn interacts with and promotes ubiquitination and degradation of the tumor suppressor MYCT1, thereby driving AML cell proliferation and inhibiting apoptosis and differentiation.\",\n      \"method\": \"Promoter binding assay (ChIP/luciferase inferred from context), gain/loss-of-function, co-immunoprecipitation, ubiquitination assay, in vivo AML mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter activation and protein interaction demonstrated, epistatic rescue with MYCT1 knockdown, in vivo validation; single lab\",\n      \"pmids\": [\"40533483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"POU2F2 directly binds the PREX1 promoter and activates its transcription in AML cells, promoting mTOR pathway activation and AML malignant progression; PREX1 knockdown reverses POU2F2 overexpression-driven effects, establishing POU2F2 upstream of PREX1/mTOR in AML.\",\n      \"method\": \"Dual-luciferase assay, ChIP assay, Western blot, colony formation/CCK-8/Transwell assays, xenograft tumor model\",\n      \"journal\": \"Journal of biochemical and molecular toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding (dual-luciferase + ChIP), epistatic rescue, in vivo xenograft; single lab\",\n      \"pmids\": [\"40317800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In the THBS1-mediated diabetic osteoporosis pathway, PPARγ (activated downstream of CD36) transcriptionally upregulates POU2F2, which then enhances osteoclastogenesis via c-FOS induction; genetic ablation of THBS1 or virtual screening inhibitor nasunin suppressed this CD36-PPARγ-POU2F2-c-FOS axis and reduced bone loss in T2D mice.\",\n      \"method\": \"ChIP-qPCR for PPARγ binding to POU2F2 promoter, Western blot, flow cytometry, TRAP staining, micro-CT, in vivo T2D mouse model, virtual screening\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP evidence for upstream regulation of POU2F2 by PPARγ, in vivo genetic ablation with bone phenotype readout; single lab\",\n      \"pmids\": [\"41407214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In multiple myeloma, POU2F2 binds eccANKRD28 (an active enhancer eccDNA) and forms a protein complex with RUNX1 and RUNX2 to activate the promoters of oncogenes including IRF4, JUNB, IKZF3, RUNX3, and BCL2, driving bortezomib/lenalidomide resistance; CRISPR/Cas9-mediated elevation of eccANKRD28 desensitizes cells to treatment.\",\n      \"method\": \"H3K27ac ChIP-seq, scRNA-seq, scATAC-seq, CUT&Tag, CRISPR/Cas9, in vitro and in vivo drug resistance assays\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-omics binding evidence and functional CRISPR validation; POU2F2-RUNX complex formation inferred from motif co-occupancy rather than direct Co-IP; single lab\",\n      \"pmids\": [\"40167268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"POU2F2 is a crucial transcription factor mediating MIF-driven activation of SPP1+ tumor-associated macrophages in colorectal cancer; BCL9L is identified as a direct downstream transcriptional target of POU2F2 in this context, and blocking MIF signaling abolishes SPP1+TAM activation in vitro and in vivo.\",\n      \"method\": \"scRNA-seq interaction analysis, TAM co-culture model, liver metastasis in vivo model, mechanistic studies identifying POU2F2 as transcriptional regulator of BCL9L\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanistic details for POU2F2-BCL9L binding not fully described in abstract; single lab, limited methodological detail\",\n      \"pmids\": [\"41800265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"POU2F2 directly binds to and activates the SPOCD1 promoter in lung adenocarcinoma cells (demonstrated by dual-luciferase, ChIP, and DNA pulldown assays), thereby enhancing PI3K/AKT pathway signaling and promoting cell proliferation; exercise suppresses POU2F2 expression, disrupting this axis.\",\n      \"method\": \"Dual-luciferase assay, ChIP assay, DNA pulldown, shRNA knockdown, CCK-8/EdU/flow cytometry/TUNEL assays, xenograft model with Ki67 IHC\",\n      \"journal\": \"Clinical & translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding by three orthogonal methods (luciferase, ChIP, DNA pulldown), in vivo validation; single lab\",\n      \"pmids\": [\"41795741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Genetic loss of Pou2f2 in mouse spinal cord results in impaired development of two early-born motor neuron columns and re-specification of anterolateral system projection neurons as a later-born subset, placing Pou2f2 in a conserved sequential transcription factor cascade (Onecut2 → Pou2f2 → Pou3f1) that controls chronological diversification of spinal neuron subtypes.\",\n      \"method\": \"Conditional/constitutive mouse knockout, immunofluorescence for motor neuron and projection neuron markers, genetic epistasis analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined neuronal phenotype and pathway placement; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.05.27.656404\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"POU2F2 (OTF-2) is a B cell-enriched POU-homeodomain transcription factor that binds octamer sequences (5'-ATGCAAAT) through its POU domain to activate immunoglobulin gene transcription and MHC class II (DRA) gene expression, possessing two structurally distinct transactivation domains (a C-terminal proline-rich domain and an upstream PQL domain); beyond B cells, it directly binds and activates the promoters of numerous target genes (PDPK1, AGO1, ROBO1, MARCH1, PREX1, PIK3CD, SPOCD1, PTPRG-AS1, SLC3A2) to regulate glycolytic reprogramming, AKT/mTOR signaling, cancer cell proliferation and metastasis, and ferroptosis; it also acts as a temporal transcription factor in retinal and spinal neuronal progenitors, where it represses the rod-fate determinant Nrl and controls the chronological order of neuron subtype production downstream of Onecut factors.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"POU2F2 (OTF-2) is a POU-homeodomain transcription factor first identified as a B-cell factor that binds the octamer sequence 5'-ATGCAAAT and activates immunoglobulin gene transcription [#0]. It engages octamer-containing promoters through DNA contacts that are biochemically indistinguishable from the ubiquitous OTF-1, yet drives full B-cell-specific transcription only in cooperation with additional B-cell-restricted factors, indicating that promoter selectivity arises from combinatorial partnerships rather than intrinsic binding differences [#2, #3]. High-level activation requires two structurally distinct transactivation domains \\u2014 a C-terminal proline-rich domain and an upstream domain in which clustered glutamine and leucine residues are individually essential [#1]. Beyond immunoglobulin loci, POU2F2 octamer-dependently activates the MHC class II gene DRA [#6], and its nuclear binding activity is modulated downstream of LPS and surface-Ig signaling, linking it to B-cell activation pathways [#4, #5]. Loss-of-function mutations in POU2F2 contribute to follicular lymphoma pathogenesis [#7]. In neuronal development, Pou2f2 acts as a temporal transcription factor downstream of Onecut factors: in retina it represses the rod-fate determinant Nrl to expand cone production [#9], and in spinal cord it operates within a sequential Onecut2\\u2192Pou2f2\\u2192Pou3f1 cascade controlling the chronological diversification of interneuron and motor neuron subtypes [#10, #11, #26]. In cancer, POU2F2 functions broadly as an oncogenic transcriptional activator that directly binds and induces target promoters \\u2014 including PDPK1, AGO1, PREX1, SPOCD1, MARCH1, ROBO1 and PIK3CD \\u2014 to drive PI3K/AKT/mTOR signaling, aerobic glycolysis, proliferation and metastasis [#8, #12, #13, #18, #20, #21, #25], and it also acts as a transcriptional repressor of SLC3A2 modulating ferroptosis [#19].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Established the existence of a dedicated B-cell octamer-binding transcription factor for immunoglobulin genes, answering what protein activity drives kappa light chain transcription.\",\n      \"evidence\": \"Affinity purification to homogeneity, DNA-binding renaturation assay, and in vitro transcription from a kappa promoter\",\n      \"pmids\": [\"3119226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the activation domains or sequence of the factor\", \"Cooperating B-cell-specific components not yet identified\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Mapped how POU2F2 activates transcription, showing two structurally constrained transactivation domains rather than a single composition-dependent activator.\",\n      \"evidence\": \"Site-directed mutagenesis of OTF-2 cDNA with reporter assays in non-lymphoid cells\",\n      \"pmids\": [\"2328729\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Coactivators contacted by each domain not identified\", \"Structural basis of glutamine/leucine cluster requirement unresolved\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Resolved the puzzle of why POU2F2 and ubiquitous OTF-1 bind octamers identically yet only POU2F2 confers B-cell-specific transcription, attributing specificity to cooperating B-cell factors.\",\n      \"evidence\": \"DNase footprinting, EMSA, and reconstituted in vitro transcription with purified factors in OTF-depleted extracts; identification of cooperating N-element factor (NTF)\",\n      \"pmids\": [\"2123291\", \"2109187\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NTF/cooperating factor not molecularly identified\", \"Direct protein-protein contact with POU2F2 inferred but not demonstrated\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Extended POU2F2 target repertoire beyond immunoglobulin genes to MHC class II, showing octamer-dependent activation distinct from OTF-1.\",\n      \"evidence\": \"In vitro reconstitution, recombinant protein, transfection, and octamer-element mutation of the DRA promoter\",\n      \"pmids\": [\"1560002\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide target scope unknown at this stage\", \"Cell-type determinants of selectivity not addressed\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Placed POU2F2 downstream of B-cell activation signals by linking its nuclear binding activity to LPS and surface-Ig crosslinking.\",\n      \"evidence\": \"EMSA and immunofluorescence on stimulated B cells, genetic variant cell line, reporter assays\",\n      \"pmids\": [\"1689272\", \"1658749\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of signal-induced nuclear translocation not defined\", \"Single-method localization evidence per finding\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Implicated POU2F2 in human disease by showing lymphoma-associated mutations alter its transcriptional function.\",\n      \"evidence\": \"Exome sequencing, luciferase reporters, stable transduction, and expression profiling in follicular lymphoma\",\n      \"pmids\": [\"24435047\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal driver status versus passenger mutation not fully resolved\", \"Affected downstream gene programs only partly defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a developmental function as a temporal transcription factor, showing Pou2f2 represses Nrl to control cone-versus-rod photoreceptor fate timing.\",\n      \"evidence\": \"Promoter binding, conditional knockout, and retroviral misexpression in mouse retina with cone/rod quantification\",\n      \"pmids\": [\"32878923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect repression mechanism at Nrl not fully dissected\", \"Cofactors mediating repression unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Positioned Pou2f2 within an Onecut-controlled genetic cascade governing spinal interneuron and motor neuron diversification.\",\n      \"evidence\": \"Gain/loss-of-function in mouse spinal cord with interneuron marker immunofluorescence; preprint extension to motor neuron columns and a Onecut2\\u2192Pou2f2\\u2192Pou3f1 cascade\",\n      \"pmids\": [\"31231191\", \"31787878\", \"bio_10.1101_2025.05.27.656404\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets in neurons not identified\", \"Spinal cord temporal cascade work partly preprint, not peer-reviewed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established POU2F2 as a broad oncogenic transcriptional activator driving PI3K/AKT/mTOR signaling, glycolysis, proliferation and metastasis across diverse cancers via direct promoter activation of specific targets.\",\n      \"evidence\": \"ChIP, luciferase/dual-luciferase, DNA pulldown, knockdown with target reconstitution rescues, and xenograft/metastasis models across gastric, glioblastoma, lung, AML, breast, and other cancers\",\n      \"pmids\": [\"26019213\", \"33931589\", \"33832481\", \"39401868\", \"40533483\", \"40317800\", \"41795741\", \"38318853\", \"40167268\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Unifying determinants of which targets POU2F2 selects in a given tissue unclear\", \"Repressor versus activator mode switching mechanism (e.g. SLC3A2) not mechanistically explained\", \"Most findings are single-lab, single-cancer studies\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How POU2F2 switches between transcriptional activation and repression and selects context-specific targets across immune, neuronal, and cancer settings remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking cofactor binding to activator/repressor output\", \"Genome-wide occupancy comparisons across cell types not integrated\", \"Mechanism of upstream regulation (NF-\\u03baB, PPAR\\u03b3, CBX7, miR-218) on POU2F2 levels incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 6, 9, 12, 19]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 6, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 6, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 6, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9, 10, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 18, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 8, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RUNX1\", \"RUNX2\", \"CEBPB\", \"HOXA11-AS\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}